Clonal analysis of B-cell response in pemphigus course: toward more effective therapies.
In this issue, Hammers et al. report the first longitudinal study of B-cell responses in pemphigus vulgaris. They show persistence of the same sets of anti-desmoglein 3 (Dsg3) B-cell clones over time in two patients with active disease, suggesting that escape from tolerance is not a frequent event. In addition, the disappearance of anti-Dsg3 B-cell clones in two patients during long-term rituximab-induced remission supports the therapeutic potential of rituximab.